Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment

N Engl J Med. 2019 May 30;380(22):2178-2180. doi: 10.1056/NEJMc1815121.

Authors

Margaretha de Vos¹, Serej D Ley¹, Kristin B Wiggins², Brigitta Derendinger³, Anzaan Dippenaar³, Melanie Grobbelaar³, Anja Reuter⁴, Tania Dolby⁵, Scott Burns⁶, Marco Schito⁷, David M Engelthaler², John Metcalfe⁸, Grant Theron³, Annelies van Rie⁹, James Posey⁶, Rob Warren¹⁰, Helen Cox¹¹

Affiliations

¹ Stellenbosch University, Cape Town, South Africa margab@sun.ac.za.
² Translational Genomics Research Institute, Flagstaff, AZ.
³ Stellenbosch University, Cape Town, South Africa.
⁴ Médecins sans Frontières, Cape Town, South Africa.
⁵ National Health Laboratory Services, Cape Town, South Africa.
⁶ Centers for Disease Control and Prevention, Atlanta, GA.
⁷ Critical Path Institute, Tucson, AZ.
⁸ University of California, San Francisco, San Francisco, CA.
⁹ University of Antwerp, Antwerp, Belgium.
¹⁰ South African Medical Research Council, Cape Town, South Africa.
¹¹ University of Cape Town, Cape Town, South Africa.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antitubercular Agents / therapeutic use*
Diarylquinolines / therapeutic use*
Drug Resistance*
Drug Therapy, Combination
Humans
Male
Mycobacterium tuberculosis / drug effects
Mycobacterium tuberculosis / genetics*
Mycobacterium tuberculosis / isolation & purification
Tuberculosis, Multidrug-Resistant / drug therapy*
Whole Genome Sequencing

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline

Grants and funding